lonidamine
Small moleculeexperimental
Lonidamine is a derivative of indazole-3-carboxylic acid, which for a long time, has been known to inhibit aerobic glycolysis in cancer cells. It seems to enhance aerobic glycolysis in normal cells, but suppress glycolysis in cancer cells. This is most likely through the inhibition of the mitochondrially bound hexokinase. Later studies in Ehrlich ascites tumor cells showed that lonidamine inhibits both respiration and glycolysis leading to a decrease in cellular ATP. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2005 (NCT00237536)
Timeline
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12- Mol. weight
- 321.16 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLonidamine ↗
- ChEMBLCHEMBL1257030 ↗
Also known as
- 1-(2,4-dichlorobenzyl)indazole-3-carboxylic acid
- 1h-indazole-3-carboxylic acid, 1-((2,4-dichlorophenyl)methyl)-
- af 1890
- diclondazolic acid
- diclondazolic acid
- doridamina
- doridamina
- doridamina
- doridamina
- lonidamine
- lonidamine
- lonidamine
- lonidamine
- lonidamine
- lonidamine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00237536 | Phase 2 | Jun 1, 2005 | Threshold Pharmaceuticals |
| NCT00435448 | Phase 3 | Jun 1, 2005 | Pharmaceutical Research Associates, Inc. (PRA), Threshold Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Threshold Pharmaceuticals | For profit | 2 | 2 | 2 | 2005 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2005 |
2 organizations
Page 1 / 1